Cholesterol and lipid medicines

Hypolipidaemic agents

Find reliable independent health and treatment information about the cholesterol and lipid medicines subcategory of medicines. This includes resources for consumers and health professionals.

The Cholesterol and lipid medicines subcategory of medicines is also known as anticholesteraemic agents, cholesterol lowering medicines, dyslipidaemia, medicines for, lipid-lowering medicines, lipid-modifying medicines and hypolipidaemic agents.

You can also search for an active ingredient, brand or other category of medicine using our Medicine Finder.

Latest information - cholesterol and lipid medicines

Audience:
       

(Media release)
14 Feb 2014 NPS MedicineWise is reminding health professionals that while various media reports have recently linked statins to a variety of adverse events and questioned their efficacy, these drugs remain one of the most effective strategies for reducing the risk of cardiovascular disease (CVD).
(Media release)
14 Feb 2014 NPS MedicineWise is reminding health professionals and the general public that the cholesterol-lowing medicines statins remain one of the most effective strategies for reducing the risk of heart attack and stroke.
For health professionals (Health professional publication)
01 Feb 2014 For people under 75, starting treatment with statins should be based on their absolute CVD risk. Find out who needs a risk calculation, who is assumed to be at high risk of cardiovascular events and what the treatment recommendations are.
(Media release)
06 Dec 2013 With the statins group of cholesterol-lowering medicines continuing to make headlines this week, independent organisation NPS MedicineWise has reviewed the latest clinical evidence and published a set of Frequently Asked Questions (FAQs) on its website addressing people’s key concerns.
(Media release)
02 Dec 2013 Cholesterol-lowering medicines known as statins top the list of the top 10 subsidised drugs in Australia again this year, according to data published in Australian Prescriber.
(Media release)
01 Nov 2013 Public debate — sparked by the ABC Catalyst program — on whether management of cardiovascular risk places undue emphasis on blood cholesterol has raised questions about current prescribing practices for lipid lowering medicines and the role of statins in the prevention of cardiovascular events.
(Media release)
01 Nov 2013 In response to public debate about the role of statins in reducing heart attack and stroke in people at risk of cardiovascular disease, NPS MedicineWise is urging people not to stop taking their medicine without talking to their doctor first.
(Condition)
30 Oct 2013 Cardiovascular disease includes heart attack, stroke and other blood vessel diseases. It is Australia's biggest killer — killing more than either cancer or road accidents.
For health professionals (Tool / resource)
30 Oct 2013 Statins remain one of the most effective strategies for reducing the risk of cardiovascular disease, but patient selection is key
For health professionals (Health professional publication)
16 Sep 2013 For people under 75, starting treatment with statins should be based on their absolute CVD risk. Find out who needs a risk calculation, who is assumed to be at high risk of cardiovascular events and what the treatment recommendations are.

Active ingredients used in cholesterol and lipid medicines